Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)

NCT ID: NCT02805881

Last Updated: 2021-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2021-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neurolief System treatment

Treatment with the Neurolief system will be applied by the subject at his home and/or surrounding daily during a period of six weeks

Group Type EXPERIMENTAL

Neurolief system

Intervention Type DEVICE

Non-invasive cephalic neurostimulation device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neurolief system

Non-invasive cephalic neurostimulation device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The subject is capable of understanding the study and to sign an informed consent.
* Subject is between the ages of 18 to 65 years old.
* Unipolar major depressive disorder
* Score on the Hamilton Depression Rating Scale (HDRS21) \> 22
* Current MDD episode \>3 months
* Nonresponse with \>6 week use of one to six antidepressant in current episode

Exclusion Criteria

* History of neurosurgical interventions.
* Subjects with metal implants or shrapnel in their head, except for dental implants.
* Skin lesion or inflammation at the region of the stimulating electrodes.
* Pregnancy or Lactation.
* Women of reproductive age not using efficient contraceptive method.
* History of cerebrovascular event.
* Psychotic or bipolar depression
* History of schizophrenia, schizoaffective disorder or other non-mood disorder psychosis
* Current delirium, dementia, amnestic disorder or other cognitive disorders
* Clinically significant current suicidal intent as assessed by the investigator team.
* Obsessive-compulsive disorder or post-traumatic stress disorder
* Alcohol and non-alcohol psychoactive substance abuse or dependence
* Significant cardiac, medical, or progressive neurological or medical illness
* An implantable electrical device such as a pacemaker.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Neurolief Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hilik Levkovitz, Prof.

Role: PRINCIPAL_INVESTIGATOR

Deputy Director, Beer- Yakov Nees-Ziona Mental Health Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beer- Yakov Nees-Ziona Mental Health Center

Ness Ziona, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NRLF-BY531-CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Adaptive tDCS for Treatment-Resistant MDD
NCT02942368 ACTIVE_NOT_RECRUITING NA